Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D, Abbate R, Gensini GF.

Am J Cardiol. 2009 Mar 15;103(6):806-11. doi: 10.1016/j.amjcard.2008.11.048. Epub 2009 Jan 24.

PMID:
19268736
2.

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.

Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2010 Jun 1;55(22):2427-34. doi: 10.1016/j.jacc.2010.02.031.

3.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
5.

Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.

Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G.

JACC Cardiovasc Interv. 2013 Nov;6(11):1166-75. doi: 10.1016/j.jcin.2013.06.010.

6.
7.

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.

Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N.

Eur Heart J. 2009 Apr;30(8):916-22. doi: 10.1093/eurheartj/ehp041. Epub 2009 Feb 4.

PMID:
19193675
8.

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.

9.

Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.

Sawada T, Shinke T, Shite J, Honjo T, Haraguchi Y, Nishio R, Shinohara M, Toh R, Ishida T, Kawamori H, Kozuki A, Inoue T, Hariki H, Hirata K.

Circ J. 2011;75(1):99-105. Epub 2010 Nov 16.

10.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

PMID:
21527445
11.

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A.

Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.

12.
14.

Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.

Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS.

Heart. 2012 Jan;98(2):139-44. doi: 10.1136/hrt.2011.227272. Epub 2011 Jun 23.

PMID:
21700758
16.

Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.

Zou JJ, Xie HG, Chen SL, Tan J, Lin L, Zhao YY, Xu HM, Lin S, Zhang J, Wang GJ.

Eur J Clin Pharmacol. 2013 Apr;69(4):771-7. doi: 10.1007/s00228-012-1392-5. Epub 2012 Sep 22.

PMID:
23001453
17.

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G.

Lancet. 2009 Jan 24;373(9660):309-17. doi: 10.1016/S0140-6736(08)61845-0. Epub 2008 Dec 26.

PMID:
19108880
18.

Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.

Roy P, Bonello L, Torguson R, Okabe T, Pinto Slottow TL, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R.

Am J Cardiol. 2009 Mar 15;103(6):801-5. doi: 10.1016/j.amjcard.2008.11.038. Epub 2009 Jan 24.

PMID:
19268735
19.

Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.

Hwang SJ, Jeong YH, Kim IS, Park KS, Kang MK, Koh JS, Park JR, Park Y, Koh EH, Kwak CH, Hwang JY, Kim S.

Circ Cardiovasc Interv. 2010 Oct;3(5):450-9. doi: 10.1161/CIRCINTERVENTIONS.110.949859. Epub 2010 Sep 7.

20.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W.

Arch Cardiovasc Dis. 2013 Oct;106(10):517-27. doi: 10.1016/j.acvd.2013.06.055. Epub 2013 Sep 27. Review.

Supplemental Content

Support Center